Key result
Vasodilators fail to reduce all-cause mortality in acute heart failure.
Why the study?
Acute heart failure is a public health concern, prompting a systematic review to evaluate the role of vasodilators.
Do vasodilators reduce all-cause mortality in patients with acute heart failure?
Population
Patients with acute heart failure in RCTs
Comparison
Vasodilators vs standard care, placebo, or cointerventions
Design
Systematic review and meta-analysis of RCTs
Authors
Loading...
No mortality benefit from vasodilators in acute HF; confirms neutral survival effect across RCTs.
Meta-Analysis
Do vasodilators reduce all-cause mortality in patients with acute heart failure?
In patients with acute heart failure, the use of vasodilators does not reduce all-cause mortality.
Lukoschewitz et al. (2024) conducted a meta-analysis in Acute heart failure. Vasodilators vs. Standard care, placebo, or cointerventions was evaluated on All-cause mortality. Vasodilators did not reduce all-cause mortality compared with no receipt of vasodilators in patients with acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: